APA (7th ed.) Citation

J, S., F, G., R, R., L, V. G., J, B., M, L., . . . R, P. (2015). Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: Results from an open-ended, open-label extension trial. Pituitary, 18(5), 604. https://doi.org/10.1007/s11102-014-0618-1

Chicago Style (17th ed.) Citation

J, Schopohl, et al. "Pasireotide Can Induce Sustained Decreases in Urinary Cortisol and Provide Clinical Benefit in Patients with Cushing's Disease: Results from an Open-ended, Open-label Extension Trial." Pituitary 18, no. 5 (2015): 604. https://doi.org/10.1007/s11102-014-0618-1.

MLA (9th ed.) Citation

J, Schopohl, et al. "Pasireotide Can Induce Sustained Decreases in Urinary Cortisol and Provide Clinical Benefit in Patients with Cushing's Disease: Results from an Open-ended, Open-label Extension Trial." Pituitary, vol. 18, no. 5, 2015, p. 604, https://doi.org/10.1007/s11102-014-0618-1.